Lipigo 20 Tablet contains Rosuvastatin 20 mg, a potent lipid-lowering agent belonging to the statin class of medications. It is primarily indicated for the treatment of hypercholesterolemia and mixed dyslipidemia to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased cholesterol production in the liver and increased clearance of LDL particles from the bloodstream. Lipigo 20 is prescribed as an adjunct to diet and lifestyle modifications, including exercise, weight control, and smoking cessation, to reduce the risk of cardiovascular events such as myocardial infarction, stroke, and angina in patients with atherosclerotic cardiovascular disease or those at high risk. The recommended dosage should be individualized based on patient response and tolerability, with regular monitoring of lipid profiles, liver function tests, and creatine kinase levels to detect potential adverse effects. Common side effects include headache, myalgia, and gastrointestinal disturbances. Caution is advised in patients with hepatic impairment, renal dysfunction, or a history of muscle disorders. Lipigo 20 Tablet should be used under medical supervision to optimize therapeutic outcomes and minimize risks.